ORIGINAL RESEARCH

Demographic, procedural and 30-day safety results from the WEB Intra-saccular Therapy Study (WEB-IT)

David Fiorella,1 Andrew Molyneux,2 Alexander Coon,3 Istvan Szikora,4 Isil Saatci,5 Feyyaz Baltacioglu,6 Ali Sultan,7 Adam Arthur,8 for the WEB-IT Study Investigators

ABSTRACT

Introduction The Woven EndoBridge (WEB) represents a novel intrasaccular therapeutic option for the treatment of intracranial wide-necked bifurcation aneurysms (WNBAs). The WEB-IT Study is a pivotal Investigational Device Exemption (IDE) study to determine the safety and effectiveness of the WEB device for the treatment of WNBAs located in the anterior and posterior intracranial circulations. We present the patient demographics, procedural characteristics, and 30-day adverse event data for the US WEB-IT study.

Methods WEB-IT is a prospective multicenter single-arm interventional study conducted at 25 US and 6 international centers. The study enrolled 150 adults with WNBAs of the anterior and posterior intracranial circulations. All patients were intended to receive a WEB device delivered via standard endovascular neurosurgical embolization techniques. The study was conducted under Good Clinical Practices and included independent adjudication effectiveness outcomes and all adverse events.

Results One hundred and fifty patients enrolled at 27 investigational sites underwent attempted treatment with the WEB. Mean age was 59 years (range 29–79) and 110 (73.3%) of the patients were female. Treated aneurysms were located at the basilar apex (n=59, 39.3%), middle cerebral artery bifurcation, internal carotid artery terminus (n=45, 30%), anterior communicating artery (n=40, 26.7%), and anterior carotid artery terminus (n=6, 4%). Average aneurysm size was 6.4 mm (range 3.6–11.4) with a mean neck size of 4.8 mm (range 2.0–8.2, mean dome to neck ratio 1.34). Nine patients presented with ruptured aneurysms. Of the enrolled patients, 98.7% were treated successfully with WEB devices. Mean±SD fluoroscopy time was 30.2±15.7 min. One primary safety event (PSE) (0.7%)—a delayed parenchymal hemorrhage 22 days after treatment—occurred between the index procedure and 30-day follow-up. In addition to the single PSE, there were seven (4.7%) minor ischemic strokes (5 resolved without sequelae and 2 had a modified Rankin Scale score of 1 at 30 days), five (2.7%) transient ischemic attacks, and two (1.3%) minor subarachnoid hemorrhages, which did not meet the prospectively established criteria for PSEs.

Conclusions The WEB device can be used to treat WNBAs with a high level of procedural safety and a high degree of technical success.

Trial registration number NCT02191618; Pre-results.

METHODS

Study design

The WEB-IT Study is a prospective multicenter single-arm interventional study conducted at 25 US and 6 international centers. The study enrolled 150 adults with WNBAs of the anterior and posterior intracranial circulations. The study protocol was approved by each center’s IRB and all patients submitted written informed consent. The study was conducted under Good Clinical Practices (GCP) and included independent adjudication of all AEs. An independent core laboratory adjudicated effectiveness outcomes. A Data Monitoring Committee conducted study safety reviews.

A detailed set of inclusion and exclusion criteria are included in the online supplementary materials. Required aneurysm characteristics were:

1. Ruptured or unruptured
2. Saccular in shape
3. Located at the basilar apex (BA), middle cerebral artery (MCA) bifurcation, internal carotid artery terminus (ICAt), anterior communicating artery complex (ACom)
4. Dome to neck ratio ≥1
5. Wide-necked intracranial aneurysm with neck size ≥4 mm or dome to neck ratio <2
6. Diameter appropriate for treatment with the WEB device per device instructions for use.

Patients with ruptured aneurysms were required to be neurologically stable with a Hunt & Hess (H&H) score of 1 or 2. Key exclusion criteria included: vascular tortuosity or morphology which could preclude safe access and support during treatment with WEB, and modified Rankin Scale (mRS) score ≥2 at baseline or prior to rupture.

Device characteristics

The WEB Aneurysm Embolization System (Sequent Medical, Aliso Viejo, California, USA) consists of a family of self-expanding embolization implants developed specifically for the treatment of WNBAs. The WEB Single Layer (SL) and WEB Single Layer Sphere (SLS) models are composed of single layers of braided nitinol/platinum wires. The braids are joined at the proximal and distal ends of the device by radiopaque platinum markers. The WEB Double Layer (DL) is a mesh sphere composed of two layers of braided nitinol wires. The inner and outer layers of braid are joined by proximal, middle, and distal platinum markers (Figure 1). The implant is attached to a flexible delivery wire. Detachment of the implant is electrothermal, similar to several other commercially available neurovascular implant delivery systems. WEB devices ranging between 4×3 mm and 11×9 mm were available for use within the WEB-IT protocol.

Procedures

All enrolled patients underwent a standard neuroendovascular procedure (triaxial approach) with the intent of delivering and implanting a WEB device into the index aneurysm. Antiplatelet therapy was recommended based on the publication of Spelle and Liebig.13 Patients were considered to be ‘enrolled in WEB-IT’ with the intention to treat when the WEB device was introduced into the microcatheter during the procedure. Two-dimensional (2D) and three-dimensional (3D) digital subtraction angiography (DSA) was performed to confirm the final device position. Inability to deploy a WEB and the use of implanted adjunctive devices (ie, coils or stents) were considered effectiveness failures. Clinical follow-up was conducted at 30 days, 6 months, 1 year, and annually to 5 years. Follow-up 2D and 3D DSA was performed at 6 months and 1 year.

Study endpoints

Per protocol safety and effectiveness will be assessed at the 1 year follow-up. The study’s primary effectiveness endpoint is the proportion of patients with complete aneurysm occlusion without retreatment, recurrent subarachnoid hemorrhage (SAH), or significant parent artery stenosis (>50% stenosis) at 1 year after treatment.14 The study’s primary safety endpoint is the proportion of patients with primary safety events (PSEs) which includes death from any non-accidental cause or any major stroke (defined as an ischemic or hemorrhagic stroke resulting in an increase of ≥4 points on the National Institutes of Health Stroke Scale persisting for 7 days after the procedure) within the first 30 days after treatment or major ipsilateral stroke or neurologic death from day 31 to 1 year after treatment.

The study’s secondary effectiveness endpoint is the proportion of patients with angiographic aneurysmal recurrence defined as aneurysm growth or recanalization at 1 year after treatment. This proportion will be presented descriptively with the rate and its exact 95% CI.

Statistical analyses

This paper reports the study design, patient demographics, procedural characteristics, and 30-day AE information only. No statistics or formal analyses were performed.

RESULTS

Patient disposition

One hundred and eighty patients met the initial screening criteria and consented to participate. There were 30 screening failures, the most common reasons being aneurysm characteristics such as size and morphology. One hundred and fifty patients were therefore enrolled at 27 investigational sites. All enrolled patients underwent an interventional procedure with the intention of treating with the WEB device. These data are included in the present 30-day safety analysis (Figure 2).

Patient demographic and baseline characteristics

All patients were enrolled between August 2014 and March 2016. The baseline characteristics are summarized in Table 1. Baseline aneurysm characteristics are shown in Table 2.

Mean age at treatment was 59±0.83 years (range 29–79 years); 73.3% were female. Nine patients presented with ruptured aneurysms; six were H&H 1 and three were H&H 2.
Ninety-eight (65.3%) were current or past smokers. One hundred and sixteen patients (77.3%) were enrolled at US sites while 34 (22.7%) were enrolled at international sites. The predominant pre-existing conditions included hypertension in 64%, a history of headaches/migraines in 38%, and hyperlipidemia in 25.3%. Eighteen (12.0%) had a history of ischemic stroke, 10 (6.7%) had a history of hemorrhagic stroke, and nine (6.0%) had a history of transient ischemic attack (TIA).

With respect to aneurysm characteristics (table 2), 91 (60.7%) were located in the anterior circulation and 59 (39.3%) in the posterior circulation. The mean dome width was 6.4 mm (range 3.6–11.4), mean dome height was 6.1 mm (range 3.1–10.3), mean neck size was 4.8 mm (range 2.0–8.2), and mean dome to neck ratio was 1.3 (range 1.0–2.0).

Table 1 Baseline characteristics (N=150)

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at procedure (years)</td>
<td>Mean±SE 59.0±0.83, Range 29–79</td>
</tr>
<tr>
<td>Age group</td>
<td>18–35 4 (2.7%), 36–50 20 (13.3%), 51–64 75 (50.0%), 65–75 49 (32.7%), 76+ 2 (1.3%)</td>
</tr>
<tr>
<td>Gender</td>
<td>Women 110 (73.3%), Men 40 (26.7%)</td>
</tr>
<tr>
<td>Hunt &amp; Hess grade</td>
<td>0 141 (94.0%), 1 6 (4.0%), 2 3 (2.0%)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Smoker 98 (65.3%), Current 64 (42.7%), Past 34 (22.7%), Non-smokers 52 (34.7%)</td>
</tr>
<tr>
<td>Pre-existing conditions</td>
<td>Arrhythmia 7 (4.7%), Coronary artery disease 21 (14.0%), Heart failure 3 (2.0%), Hypertension 96 (64.0%), Peripheral vascular disease 5 (3.3%), Valve disease/dysfunction 4 (2.7%), Diabetes mellitus 10 (6.7%), Hypercholesterolemia 16 (10.7%), Hyperlipidemia 38 (25.3%), Hypertriglyceridermia 0 (0.0%), Headaches/migraines 57 (38.0%), Neuropathy 12 (8.0%), Seizures 6 (4.0%)</td>
</tr>
<tr>
<td>Prior CVA</td>
<td>Ischemic stroke 18 (12.0%), Hemorrhagic stroke 10 (6.7%)</td>
</tr>
<tr>
<td>Prior TIA</td>
<td>Yes 9 (6.0%), No 138 (92.0%), Unknown 3 (2.0%)</td>
</tr>
<tr>
<td>Race</td>
<td>White 98 (65.3%), Black or African American 14 (9.3%), Asian 4 (2.7%), Not available 34 (22.7%)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Not Hispanic or Latino 114 (76%), Hispanic or Latino 2 (1.3%), Not available 34 (22.7%)</td>
</tr>
</tbody>
</table>

Table 2 Aneurysm characteristics (N=150)

<table>
<thead>
<tr>
<th>Aneurysm characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysm status</td>
<td>Ruptured 9 (6.0%), Unruptured 141 (94.0%)</td>
</tr>
<tr>
<td>Aneurysm location</td>
<td>BA terminus 59 (39.3%), ICA terminus 6 (4.0%), MCA bifurcation 45 (30.0%), ACom 40 (26.7%)</td>
</tr>
<tr>
<td>Dome width (mm)</td>
<td>Mean 6.4, Median 6.3, Range 3.6–11.4</td>
</tr>
<tr>
<td>Dome height (mm)</td>
<td>Mean 6.1, Median 6.0, Range 3.1–10.3</td>
</tr>
<tr>
<td>Aneurysm neck size (mm)</td>
<td>Mean 4.8, Median 4.7, Range 2.0–8.2</td>
</tr>
<tr>
<td>Dome to neck ratio</td>
<td>Mean 1.4, Median 1.3, Range 1.0–2.0</td>
</tr>
</tbody>
</table>

CVA, cardiovascular accident; OUS, outside of the United States of America; TIA, transient ischemic attack.

Procedural and device data

All 150 patients underwent attempted endovascular treatment with the WEB. A WEB device was successfully implanted in 148 (technical success=98.7%). In two patients WEB treatment was unsuccessful; one due to anatomic tortuosity and one due to improper device size availability. Adjunctive stenting was performed in two cases where the WEB appeared to impinge upon the parent artery or adjacent branch. Adjunctive balloons were used to assist WEB positioning in five cases.

Table 3 presents key procedural data. For the 148 patients implanted, WEB procedure times averaged 20.1±21.2 min with a range of 3–215 min. The median WEB time (time from insertion of WEB to removal of WEB delivery system) was 14 min. Procedural fluoroscopy times averaged 30.2±15.7 min and radiation doses averaged 2750±2577 mGy.
Hemorrhagic stroke

Table 3  WEB times and radiation exposure data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>WEB times* (min)</th>
<th>Fluoroscopy times (total, min)</th>
<th>Fluoroscopy doses (total, mGy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean±SD (N)</td>
<td>Median, max</td>
<td>Mean±SD (N)</td>
</tr>
<tr>
<td>WEB times</td>
<td>20.1±21.2 (148)</td>
<td>14, 3, 215</td>
<td>30.2±15.7 (146)</td>
</tr>
<tr>
<td>Fluoroscopy times</td>
<td>2750±2577 (148)</td>
<td>2281</td>
<td>79, 22.746</td>
</tr>
</tbody>
</table>

*Time from insertion of WEB to removal of delivery system following detachment. WEB, Woven EndoBridge.

Table 4 provides the locations and device configurations. The most common implant location in the study was the basilar artery (39.2%), followed by the MCA (30.4%), the ACom (26.4%), and the ICA terminus (4.31%). Nineteen (12.8%) WEB implant locations were 7 mm (n=41), followed by 8 mm (N=31), 6 mm and 5 mm were implanted. The most common device diameter implanted was 7 mm (n=41), followed by 8 mm (N=31), 6 mm and 5 mm (N=28 each).

Technical events

There were 12 reported technical events involving the deployment or detachment of the WEB device. These included device failure to open or appeared twisted on deployment (n=3), WEB detachment system failure (n=3), kinked pusher (n=2), multiple attempts required for detachment (n=2), inability to resheath (n=1), and WEB appeared damaged (n=1). There were no AEs or patient sequelae as a result of any malfunction or failure and a WEB was successfully implanted in all of these cases.

Safety

Primary safety events (PSEs)

There was one PSE (0.7%) in the interval between the index procedure and post-procedure day 30. The event, a delayed ipsilateral parenchymal hemorrhage unrelated to the treated aneurysm, occurred on post-procedure day 22. The event was adjudicated as a major stroke, most likely related to antiplatelet medication and underlying cerebrovascular disease. At last follow-up the patient’s mRS score was 4.

Additional safety outcomes

There were no deaths and no unanticipated adverse device effects (UADEs). There were seven (4.7%) minor ischemic strokes; five resolved without sequelae and two were mRS 1 at 30 days. Of these, one was device-related, four were procedure-related, and two were unrelated to either the device or the procedure. There were five (2.7%) TIAs. There were three (2%) cases of arterial thrombosis in the parent or branch vessels near the WEB device. All were device-related and all resolved without sequelae. Of these, two vessels were opened with stents and the third responded to an eptiplatelet infusion.

There were two cases of intraprocedural SAH. In one case, contrast extravasation was noted intraprocedurally and, in the second, contrast extravasation was noted on CT after the procedure. In both cases the WEB device was successfully delivered and both patients were discharged without neurological symptoms.

Overall, there were 136 AEs which occurred in 65 patients, of which 24 were categorized as serious. Nine were adjudicated as device-related and 68 were procedure-related. Other common events in the 30-day period included headache (n=21, 15.4%), nausea (n=7, 5.1%), and vessel puncture site pain (n=5, 3.7%). Of all 136 AEs, 125 resolved without sequelae, 8 remain ongoing, and 3 incurred sequelae.

Morbidity and mRS status

One patient (0.7%) experienced a major stroke during the 30 day peri-procedural period—as described above—and had a mRS score of 4 at 30 days. Eight patients had increases in the mRS score of 1 point; four of these were due to minor ischemic strokes, one was due to residual post-procedure headache and shoulder pain, and one was interpreted as inter-rater variability as no events occurred.

Ruptured cases

Of the nine patients who presented with ruptured aneurysms, seven had 15 AEs; 14 of these were non-serious and 1, an incidentally discovered spinal stenosis, was serious. There was no morbidity and all events resolved without sequelae. Only one event, a procedural arterial thrombosis, was both serious and device-related. This patient underwent intra-procedural stenting of a thrombosed branch artery adjacent to the WEB and recovered uneventfully. Two procedure-related AEs were associated with a hematoma or hemorrhage at the femoral puncture site. The most common AEs were electrolyte imbalance (three events in two patients) and headache (two events in two patients).

DISCUSSION

This study shows that (1) the treatment of appropriately selected WNBAs is feasible with the WEB device in most cases; and (2) the treatment of WNBAs with the WEB device may be performed with a high level of safety.

WNBAs are among the most challenging aneurysms encountered for endovascular treatment. Their treatment frequently requires craniotomy for clipping of the aneurysm or the use of one or more temporary (ie, a balloon catheter) or permanently (ie, intravascular stent) implanted adjunctive devices. Such complex treatment strategies are technically demanding, time intensive, require multiple catheter manipulations, and are likely to be associated with higher complication rates than more straightforward coil embolization procedures. Moreover, complete occlusion of WNBAs is often difficult to achieve with conventional endovascular coiling and the occlusion achieved with
coils may not be durable. For this reason, better endovascular treatment options are needed.\textsuperscript{15}

Intrasaccular flow disruption conceptually addresses many of the shortcomings of predicate endovascular technologies for the treatment of WNBA. The WEB allows for the single-step treatment of WNBA. In a procedure which is technically more similar to straightforward coil embolization than stent-assisted coiling or balloon remodeling.\textsuperscript{16–20} Once implanted, the WEB provides considerably greater metal surface area coverage at the aneurysm neck than standard intravascular flow diverters, with coverage increasing centripetally, ranging from 55% to 100% with the WEB compared with 30–35% with standard commercially available intravascular flow diverters.\textsuperscript{21 22} This improved coverage at the aneurysm neck has the potential to provide greater levels of flow disruption within the aneurysm as well as a more robust physical lattice for neointimal growth.\textsuperscript{23} These physical characteristics might have favorable effects on both the rates of complete occlusion and the durability of the occlusions achieved. The final results of the US WEB-IT trial will provide further data regarding the efficacy and durability of WEB treatment.

**Technical success rate**

In appropriately selected aneurysms, WEB embolization was possible in nearly 100% of cases during the WEB-IT trial. Treatment failed in only two cases, one related to tortuous anatomy and the other related to the unavailability of an appropriately sized device. It is important to underscore the role of case selection in achieving these levels of technical success. De-identified images of all potential WEB-IT patients were screened according to the WEB-IT inclusion criteria and approved by study physicians prior to enrollment. In addition, most cases were proctored by more experienced WEB users. Finally, because the study was conducted primarily by WEB-naive US investigators with no roll-in cases, numerous aneurysms were replicated and the treatment practiced prior to the actual attempted treatment. As such, while the technical success rate was extremely high, this rate may not be reflective of the entire population of WNBA encountered in clinical practice.

**Procedure times**

The technically straightforward nature of many WEB cases was reflected by the brevity of the overall case times and total fluoroscopic times. Fluoroscopy times for the cases averaged approximately 30 min, and nearly one-third of the cases (n=49; 32.7%) were completed using less than 20 min of total fluoroscopic time. The WEB treatment procedure, as a single-step technique, eliminates many of the manipulations required for typical WNBA treatments. In a typical Y-stent assisted coiling case, both limbs of the bifurcation must be catheterized and stented, followed by catheterization of the aneurysm and the delivery and detachment of multiple embolization coils. For similar cases treated with WEB, the aneurysm is catheterized, a single device is delivered, assessed angiographically, and then detached. Provided that the original device selected is of an appropriate configuration (SL or SLS) and size, these cases can be completed rapidly and with a minimal number of steps and intracranial manipulations.\textsuperscript{24 25}

While more efficient from the standpoint of the actual case performance, it should be noted that the anatomical analysis of the aneurysm and selection of the optimal device configuration and size require a considerable commitment of time and cognitive effort prior to the case. In the present study, high quality angiographic imaging was essential to optimal case planning. Without detailed preoperative imaging and planning, procedure times would certainly have been higher.

**Safety of WEB-IT procedures relative to other techniques**

Consistent with previous studies, the rates of major procedural and peri-procedural complications associated with WEB treatment were low, with only a single major peri-procedural stroke observed during the study (0.7%).\textsuperscript{9 12} Moreover, this complication (a delayed lobar parenchymal hemorrhage occurring 22 days after treatment) is of uncertain relation to the actual index procedure. At the same time, rates of less severe peri-procedural ischemic events (7 minor strokes, 4.7%) and hemorrhagic events (2 SAHs, 1.4%) were similar to those reported in other studies of endovascular aneurysm treatment. Of note, only two of these patients with neurological events which did not reach the PSE criteria experienced increases in their mRS

---

**Figure 3** Procedure perforation with the Woven EndoBridge (WEB) device. A woman with an unruptured basilar apex aneurysm presented for treatment with WEB. Immediately following detachment of the Double Layer (DL) device, the microcatheter was advanced distally into the proximal aspect of the aneurysm. Angiography following the detachment demonstrated a small amount of active contrast extravasation from the aneurysm dome (A). Heparinization was reversed with protamine and a Hyperform 4×7 mm balloon (Medtronic; Irvine, California, USA) was transiently inflated within the mid-basilar artery. Angiography was repeated, demonstrating resolution of the extravasation, despite residual filling of the aneurysm (B). Cone beam CT performed at the conclusion of the treatment showed a small amount of contrast extravasation within the interpeduncular cistern (C). The patient experienced no neurological sequelae from the transient extravasation.
score (from 0 to 1) at 30-day follow-up; the others were at baseline at the 30-day assessment.

The two peri-procedural SAHs resulted in minimal symptoms despite both patients being treated with dual antiplatelet therapy at the time of their hemorrhages. This reflects the rapidity with which the WEB device is able to achieve hemostasis and aneurysm protection, even in the setting of intraprocedural hemorrhage. In one case, active extravasation was seen after the microcatheter migrated forward following WEB detachment. The observed extravasation was treated with protamine and transient inflation of a balloon within the parent artery. The extravasation ceased within minutes and the patient awoke from the procedure with no neurological symptoms (figure 3). In the second case, no extravasation was observed during the procedure but, rather, a small amount of contrast distributed within the ipsilateral subarachnoid space was noted on a post-procedure CT of the head.

When the WEB-IT data are considered together with data from WEBCAST, WEBCAST2, and the French Observatory Studies, a total of 317 patients with WNBAs have been treated with WEB devices within the context of prospective, externally adjudicated and monitored GCP studies. The combined peri-procedural safety data for these four studies yield an overall morbidity rate of 2% (5/317 patients) with no deaths. These rates are significantly lower than those reported previously in the treatment of WNBAs.

CONCLUSION
In appropriately selected WNBAs, treatment with the WEB device is both technically feasible and safe. The 30-day safety data compare favorably with other surgical and endovascular treatments for similar aneurysms. These initial short-term safety results from the US WEB-IT trial are also consistent with observations made in prior European prospective GCP trials of the WEB device.

Contributors All named authors contributed substantially to the work described by actively participating in the study and the generation of the data and providing editorial evaluation of the manuscript.

Funding Sequent Medical Inc.

Competing interests The primary investigators for the WEB IT trial received institutional salary support for study related activities. Investigators in the WEB IT trial also received payment for proctoring cases within the context of the trial.

Ethics approval US FDA, local IRBs.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Demographic, procedural and 30-day safety results from the WEB Intra-saccular Therapy Study (WEB-IT)

David Fiorella, Andrew Molyneux, Alexander Coon, Istvan Szikora, Isil Saatci, Feyyaz Ballacioglu, Ali Sultan and Adam Arthur

*J NeuroIntervent Surg* 2017 9: 1191-1196 originally published online January 17, 2017
doi: 10.1136/neurintsurg-2016-012841

Updated information and services can be found at:
http://jnis.bmj.com/content/9/12/1191

These include:

**References**
This article cites 27 articles, 13 of which you can access for free at:
http://jnis.bmj.com/content/9/12/1191#ref-list-1

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Editor's choice (76)
- Hemorrhagic stroke (331)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/